- Home
- ELVR vs RGNX Comparison
ELVR vs RGNX Comparison
Compare ELVR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVR | RGNX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.2M | 761.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ELVR | RGNX |
|---|---|---|
| Price | $65.45 | $14.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.78 |
| AVG Volume (30 Days) | 82.4K | ★ 706.5K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $146,440,045.00 | ★ $161,318,000.00 |
| Revenue This Year | $22.93 | $133.58 |
| Revenue Next Year | $7.27 | $45.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.20 | ★ 91.30 |
| 52 Week Low | $15.55 | $5.04 |
| 52 Week High | $69.99 | $15.84 |
Technical Indicators
Market Signals| Indicator | ELVR | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.11 |
| Support Level | N/A | $13.40 |
| Resistance Level | N/A | $15.31 |
| Average True Range (ATR) | 0.00 | 0.96 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 70.71 |
Price Performance
Historical ComparisonAbout ELVR Sayona Mining Limited American Depository Shares
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.